In terms of the volume status, SGLT-2 inhibitors effectively reduce the extracellular volume, which is particularly beneficial in patients with heart failure, diabetic or non-diabetic kidney disease, and chronic kidney disease. This evidence concerns the gene SLC5A2 and chronic kidney disease.